tbuckley/cabot-search huggingface dataset:
Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients
Authors: L. Brambilla, M. Bellinvia, A. Tourlaki, B. Scoppio, F. Gaiani, V. Boneschi
Journal: British Journal of Dermatology (2009)

Journal Article Intralesional vincristine as first‐line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients Get access L. Brambilla, L. Brambilla Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar M. Bellinvia, M. Bellinvia Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Monica Bellinvia. E‐mail: monicabellinvia@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar A. Tourlaki, A. Tourlaki Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar B. Scoppio, B. Scoppio Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar F. Gaiani, F. Gaiani Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar V. Boneschi V. Boneschi Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 162, Issue 4, 1 April 2010, Pages 854–859, https://doi.org/10.1111/j.1365-2133.2009.09601.x Published: 01 April 2010
Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
Authors: M. Jules Mattes, Robert M. Sharkey, Habibe Karacay, Myron S. Czuczman, David M. Goldenberg
Journal: Clinical Cancer Research (2008)

Abstract Purpose: Antibodies are effective therapeutic agents in cancer, but cures are rarely if ever obtained. Combination therapies are likely to be more effective than a single agent. In this study, the combination of a new unconjugated humanized anti-CD20 IgG, veltuzumab, with a 90Y-conjugated humanized antibody to CD22 (epratuzumab) was evaluated for the treatment of B-cell lymphoma in a nude mouse model system. Experimental Design: Nude mice were grafted with the Ramos human B-lymphoma and treatment initiated when tumors were &amp;gt;0.1 cm3. In most experiments, mice were injected first with unconjugated anti-CD20, then with 90Y-anti-CD22 1 day later. Additional weekly injections of the unconjugated veltuzumab were administered for 3 weeks. Controls included a single agent only and a nonreactive control radiolabeled antibody. Results: Unconjugated anti-CD20 veltuzumab alone did not have a significant therapeutic effect, even at a total dose of 2.5 mg per mouse. The 90Y-anti-CD22 epratuzumab alone induced marked regressions of all tumors, but they regrew in a few weeks. The combination of these agents cured ∼80% of the mice. A nonreactive control antibody labeled with 90Y, used without veltuzumab, had no therapeutic effect. The therapeutic effect of 90Y-epratuzumab required the maximum tolerated dose of radioactivity, which was 160 μCi per mouse. Conclusions: These studies illustrate how combinations of unconjugated and radioconjugated antibodies against different B-cell markers can improve therapeutic outcome, and offer a new therapeutic paradigm for the treatment of B-cell lymphomas.
EFFECT OF THE REMOVAL OF LIPIDS ON SPECIFIC PRECIPITATION
Authors: Robert C. Krueger, Michael Heidelberger
Journal: The Journal of Experimental Medicine (1950)

Horse antisera to rabbit albumin and globulins and to Type III pneumococci were extracted at low temperatures with alcohol-ether. The precipitin reactions given by these sera deprived of lipids were studied by quantitative analytical methods. With longer periods of standing and slightly higher speeds of centrifugation than those usually required for lipid-containing sera, precipitation may be made complete in immune sera from which the lipids have been removed. The function of lipids in immune reactions is discussed, as well as the effects on antibody globulin of the procedures used in their removal.
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
Authors: R J Farrell, Y Ang, P Kileen, D S O'Briain, D Kelleher, P W N Keeling, D G Weir
Journal: Gut (2000)

There is concern that the incidence of non-Hodgkin's lymphoma (NHL) will rise with increasing use of immunosuppressive therapy.Our aim was to determine the risk of NHL in a large cohort of patients with inflammatory bowel disease (IBD), and to study the association between IBD, NHL, and immunosuppressive therapy.We studied 782 IBD patients (238 of whom received immunosuppressive therapy) who attended our medical centre between 1990 and 1999 (median follow up 8.0 years). Standardised incidence ratios (SIRs) and 95% confidence intervals (CI) were calculated. Expected cases were derived from 1995 age and sex specific incidence rates recorded by the National Cancer Registry of Ireland.There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1). Our immunosuppressive group had a significantly (59 times) higher risk of NHL compared with that expected in the general population (p=0.0001). Three cases were intestinal NHL and one was mesenteric. Mean age at NHL diagnosis was 49 years, mean duration of IBD at the time of NHL diagnosis was 3.1 years, and mean duration between initiation of immunosuppressive therapy and diagnosis of NHL was 20 months.Although underlying IBD may be a causal factor in the development of intestinal NHL, our experience suggests that immunosuppressive drugs can significantly increase the risk of NHL in IBD. This must be weighed against the improved quality of life and clinical benefit immunosuppressive therapy provides for IBD patients.
A phase I trial on the ethics of phase I trials.
Authors: E J Emanuel
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.5.1049 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7738609 A phase I trial on the ethics of phase I trials. E J EmanuelxE J EmanuelSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.5.1049 First Page PDF © 1995 by American Society of Clinical OncologyKeywords: Biomedical and Behavioral ResearchEmpirical Approach... Show All
The versatility and generality of nested set operations
Authors: Richard Patterson
Journal: Behavioral and Brain Sciences (2007)

Abstract The target article makes an impressive case that nested set operations (NS) facilitate probability computations by helping make clear the relevant natural frequency partitions; however, NS can also contribute to common errors. That NS constitute a general reasoning process is supported by their role in deductive, modal, causal, and other reasoning. That NS are solely a rule-based process is problematic.
<i>TP53</i> Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Authors: Jay S. Wunder, Nalan Gokgoz, Robert Parkes, Shelley B. Bull, Sasha Eskandarian, Aileen M. Davis, Chris P. Beauchamp, Ernest U. Conrad, Robert J. Grimer, John H. Healey, David Malkin, D.C. Mangham, Michael J. Rock, Robert S. Bell, Irene L. Andrulis
Journal: Journal of Clinical Oncology (2005)

Mutations of the TP53 gene have been associated with resistance to chemotherapy as well as poor prognosis in many different malignancies. This is the first prospective study of the prognostic value of somatic TP53 mutations in patients with newly diagnosed extremity osteosarcoma.One hundred ninety-six patients with high-grade, nonmetastatic osteosarcoma of the extremities were enrolled from seven tertiary care institutions and observed prospectively for tumor recurrence (median follow-up duration, 44 months). All patients received neoadjuvant or adjuvant chemotherapy and surgery. Tumors were analyzed for the presence of TP53 mutations by polymerase chain reaction single-strand conformation polymorphism analysis and direct DNA sequencing. The association of the status of the TP53 gene with the risk of systemic recurrence was examined using survival analyses with traditional and histologic markers as prognostic factors.Patient age was the only factor that varied with TP53 gene status (P = .05). No relationship was identified between TP53 status and systemic relapse (relative risk, 1.24; P = .41). Analyses based on missense or nonsense mutations gave similar results (P > .10). In multivariate analysis, large (> 9 cm) tumor size (relative risk, 1.9; P = .006) and poor histologic response (< or = 90% necrosis) to chemotherapy (relative risk, 2.14; P = .02) were the only significant independent predictors of systemic outcome.We found no evidence that TP53 mutations predict for development of metastases in patients with high-grade osteosarcoma. Identification of other genes that influence chemotherapy response and clinical outcome in osteosarcoma is needed to facilitate further improvements in patient outcomes.
Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial
Authors: Rauf Taner Divrik, Ali F. Şahin, Ümit Yildirim, Muammer Altok, Ferruh Zorlu
Journal: European Urology (2010)
Correcting acidosis in hemodialysis
Authors: D C Harris, E Yuill, D W Chesher
Journal: Journal of the American Society of Nephrology (1995)

Control of uremic acidosis by hemodialysis carries the potential risks of reducing phosphate clearance and worsening metastatic calcification; modeling bicarbonate delivery has been proposed to adequately correct acidosis without impairing phosphate removal. To test the efficacy and safety of different methods for controlling acidosis, nine stable adults received in random order standard (S; dialysate HCO3- 30 to 34 mmol/L), high (H; 40 mmol/L) or modeled (M; 28 mmol/L, rising exponentially to 35 mmol/L at 3 h, 40 mmol/L at 4 h) bicarbonate dialysis for 4 wk each, and were tested during the last two dialyses of each treatment. More oral bicarbonate capsules were required with M than H (2.8 +/- 0.4 versus 1.4 +/- 0.4/day, P = 0.04) to maintain predialysis HCO3- at 24 to 26 mmol/L. Plasma HCO3- was significantly higher with H than M during dialysis, and than S before, during, and after dialysis. Plasma inorganic phosphate, phosphate rebound, clearance of phosphate from plasma (80 to 90 mL/min) and mass transfer of phosphate into dialysate (12 to 13 mmol/4 h dialysis) were no different among the three treatments. Similarly, there were no differences in plasma concentration of urea, total calcium, estimated ionized calcium, lipids, and potassium, clearance and mass transfer of urea, blood pressure, and symptoms with the three treatments. Estimated levels of tribasic inorganic phosphate, the phosphate component of hydroxyapatite, were very similar before and after each treatment. Plasma calcium x phosphate product was less than 3.5 mmol2/L2 at all times with each treatment. A risk factor for metastatic calcification was calculated from the relative saturation ratio of its principle component, hydroxyapatite (Ca5 (PO4)3 OH); this was no different among each of the treatments, and was not altered significantly by dialysis. Uremic acidosis can be fully corrected by high or modeled bicarbonate dialysis without any reduction of phosphate clearance or increased risk of metastatic calcification. The added cost of modeling technology is not justified by the criterion of phosphate clearance alone.
Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: The HEmochromatosis FAmily Study
Authors: Esther M.G. Jacobs, Jan C.M. Hendriks, Cees Th.B.M. van Deursen, Herman G. Kreeftenberg, Richard A. de Vries, Joannes J.M. Marx, Anton F.H. Stalenhoef, André L.M. Verbeek, Dorine W. Swinkels
Journal: Journal of Hepatology (2008)
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
Authors: Chan-Juan Shen, Yu-Xiu Yang, Ethan Q Han, Na Cao, Yun-Fei Wang, Yi Wang, Ying-Ying Zhao, Li-Ming Zhao, Jian Cui, Puja Gupta, Albert J Wong, Shuang-Yin Han
Journal: Journal of Hematology & Oncology (2013)

Abstract Background Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells appears to be a promising immunotherapeutic strategy. CAR combines the specificity of antibody and cytotoxicity of cytotoxic T lymphocytes, enhancing T cells’ ability to specifically target antigens and to effectively kill cancer cells. Recent efforts have been made to integrate the costimulatory signals in the CAR to improve the antitumor efficacy. Epidermal growth factor receptor variant III (EGFRvIII) is an attractive therapeutic target as it frequently expresses in glioma and many other types of cancers. Our current study aimed to investigate the specific and efficient antitumor effect of T cells modified with CAR containing inducible costimulator (ICOS) signaling domain. Methods A second generation of EGFRvIII/CAR was generated and it contained the EGFRvIII single chain variable fragment, ICOS signaling domain and CD3ζ chain. Lentiviral EGFRvIII/CAR was prepared and human CD3 + T cells were infected by lentivirus encoding EGFRvIII/CAR. The expression of EGFRvIII/CAR on CD3 + T cells was confirmed by flow cytometry and Western blot. The functions of EGFRvIII/CAR + T cells were evaluated using in vitro and in vivo methods including cytotoxicity assay, cytokine release assay and xenograft tumor mouse model. Results Chimeric EGFRvIIIscFv-ICOS-CD3ζ (EGFRvIII/CAR) was constructed and lentiviral EGFRvIII/CAR were made to titer of 10 6 TU/ml. The transduction efficiency of lentiviral EGFRvIII/CAR on T cells reached around 70% and expression of EGFRvIII/CAR protein was verified by immunoblotting as a band of about 57 kDa. Four hour 51 Cr release assays demonstrated specific and efficient cytotoxicity of EGFRvIII/CAR + T cells against EGFRvIII expressing U87 cells. A robust increase in the IFN-γ secretion was detected in the co-culture supernatant of the EGFRvIII/CAR + T cells and the EGFRvIII expressing U87 cells. Intravenous and intratumor injection of EGFRvIII/CAR + T cells inhibited the in vivo growth of the EGFRvIII expressing glioma cells. Conclusions Our study demonstrates that the EGFRvIII/CAR-modified T cells can destroy glioma cells efficiently in an EGFRvIII specific manner and release IFN-γ in an antigen dependent manner. The specific recognition and effective killing activity of the EGFRvIII-directed T cells with ICOS signaling domain lays a foundation for us to employ such approach in future cancer treatment.
Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer
Authors: Joseph G. Rajendran, David L. Schwartz, Janet O'Sullivan, Lanell M. Peterson, Patrick Ng, Jeffrey Scharnhorst, John R. Grierson, Kenneth A. Krohn
Journal: Clinical Cancer Research (2006)

Abstract Purpose: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. Experimental Design: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. Results: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P = 0.002), HV (P = 0.04), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUVmax, no variable was predictive at P &amp;lt; 0.05. When FDG SUVmax was removed from the model (resulting in n = 73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P = 0.02, 0.006 for node and T/Bmax, respectively; P = 0.02 and 0.001 for node and HV, respectively). Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.
FATE OF ANTIGEN-BINDING CELLS IN UNRESPONSIVE AND IMMUNE MICE
Authors: J. Louis, J. M. Chiller, W. O. Weigle
Journal: The Journal of Experimental Medicine (1973)

Antigen-binding cells (ABC) to the antigen human gamma globulin (HGG) were quantitated in lymphoid tissues of A/J mice at various times after the injection of deaggregated HGG (tolerogen), aggregated HGG (immunogen), or saline. The reaction of lymphoid cells with highly labeled HGG was specific to that antigen since binding could be inhibited by excess unlabeled HGG, but not by unrelated non-cross-reacting proteins. Compared with normal mice, there was a marked decrease in the numbers of ABC in the spleens of unresponsive animals evident as early as 12 h after the injection of tolerogen. A marked increase in ABC was observed in the spleens of immunogen-injected mice, beginning at 24 h and reaching a peak at 3 days. In bone marrow, no difference in the number of ABC was found among the three experimental groups until day 20, when a reduction in ABC was observed only in tolerogen-injected mice. No quantitative difference in the thymuses in the experimental groups could be determined because of the paucity of ABC displayed by normal thymus cells.
The Trafficking Protein GABARAP Binds to and Enhances Plasma Membrane Expression and Function of the Angiotensin II Type 1 Receptor
Authors: Julia L. Cook, Richard N. Re, Dawn L. deHaro, Jennifer M. Abadie, Michelle Peters, Jawed Alam
Journal: Circulation Research (2008)

Proteins that bind to the intracellular expanses, particularly cytoplasmic tail regions, of heptahelical integral membrane receptors are of particular interest in that they can mediate or modulate trafficking or intracellular signaling. In an effort to distinguish new proteins that might promote angiotensin II type 1 (AT(1)) receptor intracellular events, we screened a yeast 2-hybrid mouse brain library with the rat AT(1A) receptor (AT(1)R) carboxyl terminus and identified GABARAP, a protein involved in intracellular trafficking of the GABA(A) receptor, as a binding partner for the AT(1)R. Interaction of GABARAP with the AT(1)R carboxyl terminus was further substantiated using GST pull-down assays, and binding of the full-length tagged AT(1)R to GABARAP was verified using coimmunoprecipitation. Bioluminescence resonance energy transfer assays further confirmed specific interaction of GABARAP with AT(1)R. Moreover, GABARAP clearly increased the steady-state level of plasma membrane-associated AT(1)R in PC-12 cells. Cotransfection of GABARAP with an AT(1)R fluorescent fusion protein increased PC-12 cell surface expression of the AT(1)R more than 6-fold when standardized to the level of intracellular expression. Furthermore, GABARAP overexpression in CHO-K1 cells engineered to express AT(1)R increased angiotensin II binding sites 3.7-fold and angiotensin II-induced phospho-extracellular signal-regulated kinase 1/2 and cellular proliferation significantly over levels obtained with AT(1)R overexpression alone. In addition, small interfering RNA-mediated knockdown of GABARAP reduced the steady-state levels of the AT(1)R fluorescent fusion protein by 43% and its cell surface expression by 84%. Immunoblot analyses confirmed the quantitative image data. We conclude that GABARAP binds to and promotes trafficking of the AT(1)R to the plasma membrane.
Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs
Authors: E H Vogelzang, M F Pouw, M Nurmohamed, E L Kneepkens, T Rispens, G J Wolbink, C L M Krieckaert
Journal: Annals of the Rheumatic Diseases (2014)

Several factors—including immunogenicity—influence pharmacokinetics of adalimumab. The formation of antidrug antibodies (ADAb) leads to lower adalimumab trough concentrations in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA),1 ,2 and thus associated with a diminished clinical response.3 A previous paper demonstrated that methotrexate (MTX) had a dose-dependent effect on the percentage of patients that tested positive for ADAb against adalimumab.4 Moreover, prior research has shown that patients with RA concomitantly treated with MTX had higher adalimumab trough concentrations than patients without, which was also dose dependent, resulting in a more frequently achieved European League Against Rheumatism good response status.5 ,6 These studies suggest an additional beneficial effect of concomitant MTX therapy for patients with RA treated with adalimumab. However, in PsA, the benefit of MTX is not yet clear.7 Also, some patients do …
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer
Authors: J.D. Winegarden, A.M. Mauer, G.A. Otterson, C.M. Rudin, M.A. Villalona-Calero, V.J. Lanzotti, L. Szeto, K. Kasza, P.C. Hoffman, E.E. Vokes
Journal: Annals of Oncology (2004)
Abnormal Indicator Dilution Patterns in Dogs Produced by Flowmeter Probes on the Pulmonary Artery
Authors: IRWIN J. FOX, ALDO R. CASTANEDA, KENNETH C. WEBER
Journal: Circulation Research (1964)

In acute experiments on open chested dogs, indicator dilution curves were recorded before and after placing electromagnetic flow probes on the pulmonary artery. The flow probes caused severe abnormalities in the dilution curves. The abnormalities resembled those seen in cases with left-to-right shunts. The following facts suggest that the abnormalities are caused by turbulence and eddy formation near the flowmeter probe: (a) Direct measurements with a fiberoptic densitometer showed that clearance of dye just proximal to the probe was delayed. (b) The abnormalities disappeared immediately after removal of the probe or when the dye was injected just downstream to the probe. (c) The areas under curves recorded from the pulmonary artery upstream from the probe were greater than the areas under curves recorded at this same site without the probe. Cardiac output and systemic arterial pressure were lower in animals with abnormal dilution curves than in those with normal femoral curves.